ClinicalTrials.gg

Program

nesuparib

Its studies are mostly in Stomach Neoplasms · Ovarian Neoplasms, led by Jeil Pharmaceutical.

Furthest: phase 2, since Jul 13, 20224 company-led studies, 3 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jeil Pharmaceutical43 open or runningphase 2since Jul 13, 2022Jan 31, 2018none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 31, 2018First study: phase 1 study in Advanced Solid TumorsFirst studyNCT04335604 · 62 enrolled · Korea, Republic of
  2. Jul 13, 2022Phase 2 study in Ovarian NeoplasmsNCT05475184 · 58 enrolled · Korea, Republic of
  3. Jan 11, 2026Phase 2 study in Stomach NeoplasmsNCT07364422 · 49 planned · South Korea
  4. Apr 15, 2026Phase 1 study in Healthy VolunteersNCT07570186 · 36 planned · South Korea

TargetBeta

“An orally bioavailable second-generation inhibitor of the nuclear enzymes poly(ADP-ribose) polymerase (PARP) type 1 (PARP1) and 2 (PARP2) and tankyrase (TNK; TNKS; TANK) 1 and 2, ”NCIt, by rule

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07570186Healthy Volunteers · South Korea1Not yet recruitingJul 202636
NCT07364422Stomach Neoplasms · South Korea2Not yet recruitingFeb 28, 202649
NCT05475184Ovarian Neoplasms · Korea, Republic of2Active, not recruitingNov 202458
NCT04335604Advanced Solid Tumors · Korea, Republic of1CompletedDec 14, 202162

How it is read

Names in the registry

  • “JPI-547”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.